The FDA approved a proximal hypoglossal nerve stimulation device (aura6000 system) for adults with moderate to severe obstructive sleep apnea (OSA), maker LivaNova announced on Thursday. FDA's ...

LivaNova PLC (NASDAQ:LIVN) is one of the 12 Best UK Stocks to Buy According to Hedge Funds. On March 19, 2026, LivaNova PLC (NASDAQ:LIVN) announced that the FDA granted premarket approval for its ...

Fact checked by Lisa Sullivan, MS Medically reviewed by Daniel Combs, MD Key Takeaways CPAP machines can cost between $300 and $1000 or more depending on features.Inspire therapy is covered by ...

The buzz around Ozempic just got louder. A new wave of research suggests GLP-1 drugs may quietly be reshaping how doctors think about sleep apnea, one of the most underdiagnosed conditions in America.

Tirzepatide reduced sleep apnea events and improved weight loss, reshaping treatment for nighttime breathing disorders.

Incannex Healthcare Inc. (Nasdaq: IXHL) ("Incannex" or the "Company"), a clinical-stage biopharmaceutical company developing innovative ...

The disease affects as many as 80 million in the U.S. alone. Now Apnimed, the $400 million company behind the first ever pill to treat it, is preparing to file for FDA approval. In November 2016, ...

Frequent snoring can be a red flag for mild obstructive sleep apnea (OSA), a commonly undiagnosed condition. The eXciteOSA device is an FDA-authorized daytime therapy designed to strengthen tongue ...

A once-nightly oral pill helped control obstructive sleep apnea in a large, Phase III clinical trial presented at the 2026 ATS International Conference. The drug, called AD109, is the first therapy to ...

A once-nightly oral pill helped control obstructive sleep apnea in a large, phase 3 clinical trial presented at the 2026 ATS International Conference. The drug, called AD109, is the first therapy to ...

A promising new drug could put an end to cumbersome CPAP machines and allow millions of Americans to breathe easy and sleep soundly. Researchers at the biopharm company Apnimed have been developing a ...